Table 1.
Characteristics of study HCV viraemic participants
| Recruited (n = 116) | |
|---|---|
| Median age, years (IQR) | 38 (35–41) |
| Male sex (%) | 107 (92.2) |
| Anti-HIV positive, n (%) | 51 (43.9) |
| CD4 count, cells/mm3 (IQR) | 551 (275–675) |
| No ARV, n (%) | 20 (39.2) |
| Efavirienz/emtricitabine/tenofovir, n (%) | 17 (33.3) |
| Lamivudine/zidovudine/efavirenz, n (%) | 7 (13.7) |
| Tenofovir/lamivudine/efavirenz, n (%) | 7 (13.7) |
| HBsAg positive, n (%) | 9 (7.8) |
| Median ALT, IU/l (IQR) | 35 (23–51) |
| Median AST, IU/l (IQR) | 46 (32–57) |
| Median GGT, IU/l (IQR) | 69 (35–151) |
| Median total bilirubin, µmol/l (IQR) | 7 (5–10) |
| Median platelet count, ×109/l (IQR) | 188 (151–252) |
| Positive HCV RNA, n (%) | 116 (75.8) |
| Genotype (n = 110) | |
| 1a | 75 (68.2) |
| 4a | 35 (31.8) |
| Median HCV RNA (log iU/ml) | 5.7 (4.0–6.3) |
| Median HCV core Ag using serum (log fmol/l) | 2.9 (1.0–3.5) |
| Median HCV core Ag using DBS (log fmol/l) | 0.8 (0.5–1.4) |